Ryoncil — remestemcel-L
Named-patient access overview. Ryoncil is coordinated by Reserve Meds for international patients via physician-led cross-border sourcing.
About Ryoncil
Ryoncil (remestemcel-L) is manufactured by Mesoblast and indicated for Pediatric SR-aGvHD. It is a MSC cell therapy approved by the US FDA in 2024 and may be accessible to international patients through Named Patient Program or personal-import pathways.
How Reserve Meds coordinates Ryoncil
- Patient or treating physician submits a named-patient request.
- Clinical team verifies appropriateness of Ryoncil for the patient and destination country.
- Treating physician issues prescription and clinical justification.
- Country-specific NPP / personal-import documentation is prepared.
- Ryoncil is sourced from a DSCSA-compliant US specialty wholesaler with full serial traceability.
- Shipment is coordinated to the patient's physician or hospital pharmacy (cold-chain where required).
Access by country
We have documented named-patient access pathways for Ryoncil in the countries below. Each page outlines the destination-country regulatory posture, typical timeline, and physician-credential requirements.
Ryoncil in QatarNamed-patient access, timeline, and regulatory notes
Ryoncil in Saudi ArabiaNamed-patient access, timeline, and regulatory notes
Ryoncil in Sri LankaNamed-patient access, timeline, and regulatory notes
Ryoncil in TurkeyNamed-patient access, timeline, and regulatory notes
Start a request for Ryoncil
Submit a 60-second intake. Our clinical team responds within one business day with case-specific feasibility, timeline, and a formal quote.